RCEL vs SN.L
RCEL: AVITA Medical provides regenerative, point-of-care cell harvesting technology and wound management solutions to transform acute wound care. SN.L: A global medical technology leader focused on restoring patient mobility through advanced orthopedic, sports medicine, and wound care solutions.
Side-by-side fundamentals
| Metric | RCEL | SN.L | Edge |
|---|---|---|---|
| Price as of 2026-10-20 close | $13.80 | £10.88 | |
| Market cap as of 2026-08-03 (share count; price 2026-10-20) | $427M | n/a | |
| Net margin | -67.8% | +10.1% | SN.L higher |
| Gross margin | +82.1% | +68.0% | RCEL higher |
| Operating margin FY2025, SEC XBRL | -59.4% | n/a | |
| ROE FY to 2025-12-31, filed 2026-03-16 | n/a | +11.8% | |
| ROA FY2025, SEC XBRL | -86.2% | n/a | |
| Revenue growth (YoY) FY2025, SEC XBRL | +11.4% | n/a | |
| Revenue CAGR (3y) SEC XBRL | +27.7% | n/a | |
| Dividend streak (yrs) SEC XBRL | 0 | n/a | |
| Beta as of 2026-09-02 | 1.36 | n/a | |
| 1-year return as of 2026-10-20 close | +244.1% | -19.8% | RCEL higher |
Fundamentals: SEC XBRL company filings and annual report filings for the figures marked with a fiscal year, and market data, as of 2026-09-02 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-20.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.